$ANIX

KUMAR AMIT purchased $11K of ANIX

KUMAR AMIT (Chief Executive Officer) purchased 3,188 shares of Anixa Biosciences Inc (ANIX) at $3.37 on 2026-07-27.

Original reporting
SEC EDGAR · KUMAR AMIT
Published Jul 27, 2026, 7:25 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 27, 2026, 7:26 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ANIX
Bullish
medium confidence
Mentioned
$ANIX
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ANIXBullishLow
01

Why it matters

The only new information is the CEO’s reported open-market purchase details (shares, price, total value, and post-transaction holdings).

02

Market read

Traders may treat the filing as a small sentiment input, but it does not provide new guidance, trial results, or financing terms.

03

What to watch

The transaction is an open-market buy with no 10b5-1 plan and a small dollar amount, so traders should avoid over-weighting it versus upcoming clinical, financing, or earnings catalysts.

Relevance 4/10Novelty 5/10Timing: Filed 2026-07-27, same day as the reported purchase date.

Background

The article is a SEC Form 4 insider transaction disclosure for Anixa Biosciences, filed on 2026-07-27.

Company-level read

Ticker impact

$ANIXBullishMedium confidence
Context

CEO KUMAR AMIT filed a Form 4 open-market purchase of 3,188 shares at $3.37 on 2026-07-27.

Expected impact

Likely limited near-term impact; any effect is sentiment-driven and small.

Evidence & confidence

The filing is a primary-source insider transaction, but the disclosed size ($10.74k) is small relative to typical market-moving thresholds and includes no new company-specific operational or financial information.

Market effects

No direct sector read-through; this is a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

Insider purchases can be routine (e.g., liquidity planning) and do not necessarily imply improved near-term fundamentals.

Key entities

  • Anixa Biosciences Inc

    Subject of the Form 4 insider transaction disclosure.

  • KUMAR AMIT

    Chief Executive Officer and director who purchased shares.

Related articles